Artivion, Inc. (AORT) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $20.39, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Endospan; Concentration risk — Supplier: AMDS sole manufacturer.
Artivion manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgical procedures across four product families: aortic stent grafts, On-X mechanical heart valves, BioGlue surgical sealant, and preservation services. Revenue comes... Read more
Hold if already holding. Not a fresh buy at $20.39, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Endospan; Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.98B below $1B minimum. Not in investable universe. Score 6.0/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 59d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Artivion, Inc.
Latest news
- NEWS What To Expect From Artivion’s (AORT) Q1 Earnings - StockStory — StockStory neutral
- NEWS What To Expect From Artivion’s (AORT) Q1 Earnings - FinancialContent — FinancialContent neutral
- NEWS Conestoga Capital Adds Artivion to Portfolio Amid Market Volatility - HarianBasis.co — HarianBasis.co positive
- NEWS Strong Catalysts Drive Artivion (AORT) - Insider Monkey — Insider Monkey positive
- NEWS Strong Catalysts Drive Artivion (AORT) - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierEndospan10-K Item 1A: 'the NEXUS family of products are solely manufactured by Endospan in Herzliya, Israel.'
- HIGHSupplierAMDS sole manufacturer10-K Item 1A: 'The AMDS product is solely manufactured by a supplier in Charlotte, North Carolina'
- HIGHProductBioGlue10-K Item 1A: 'BioGlue is a significant source of our revenues, and as such, any risk adversely affecting our BioGlue products or business would likely be material to our financial results.'
- HIGHProductaortic stent grafts10-K Item 1A: 'Aortic stent grafts are a significant source of our revenues, and as such, any risk adversely affecting aortic stent grafts would likely be material to our financial results.'
- HIGHProductOn-X products10-K Item 1A: 'On-X products are a significant source of our revenues, and as such, any risk adversely affecting our On-X products or business would likely be material to our financial results.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $20.39, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Endospan; Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.98B below $1B minimum. Not in investable universe. Target $36.54 (+79.2%), stop $19.23 (−6.0%), A.R:R 7.5:1. Score 6.0/10, moderate confidence.
Take-profit target: $36.54 (+79.2% upside). Target $36.54 (+79.2%), stop $19.23 (−6.0%), A.R:R 7.5:1. Stop-loss: $19.23.
Concentration risk — Supplier: Endospan; Concentration risk — Supplier: AMDS sole manufacturer; Market cap $0.98B below $1B minimum.
Artivion, Inc. trades at a P/E of 80.5 (forward 26.0). TrendMatrix value score: 6.1/10. Verdict: Hold.
14 analysts cover AORT with a consensus score of 4.3/5. Average price target: $42.
What does Artivion, Inc. do?Artivion manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgical...
Artivion manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgical procedures across four product families: aortic stent grafts, On-X mechanical heart valves, BioGlue surgical sealant, and preservation services. Revenue comes from Medical Devices and Preservation Services segments sold globally, with BioGlue, aortic stent grafts, and On-X each described as significant revenue sources.